Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Litorina in connection with acquisition of Fresks
Mandate

Vinge advises Litorina in connection with acquisition of Fresks

January 15, 2016

Vinge has advised Litorina IV in connection with the acquisition of a majority shareholding in Fresks, a leading Swedish building materials and DIY chain in northern Sweden, which focuses on construction industry participants and has a turnover of SEK 875 million.

The Oscarson family and the company’s former CEO will retain a significant shareholding together with Litorina and other key personnel within the company’s management.

Vinge’s team consisted of partners Johan Winnerblad and Louise Brorsson Salomon together with, among others, associates Charlotta Järnstedt, Helena Håkansson, Emil Fahlén Godö, Jasmin Draszka-Ali and Anne Wijkman. 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024